Kopp W - Search Results

1

Relationship of large and small CD3- CD56+ lymphocytes mediating NK-associated activities.

Ortaldo JR, Winkler-Pickett R, Kopp W, Kawasaki A, Nagashima K, Okumura K, Yagita H, Bach FH. Ortaldo JR, et al. Among authors: kopp w. J Leukoc Biol. 1992 Sep;52(3):287-95. doi: 10.1002/jlb.52.3.287. J Leukoc Biol. 1992. PMID: 1381742

2

Enhanced lymphokine production and lymphokine receptor expression in multiple antibody-stimulated human CD4+ peripheral blood lymphocytes.

Conlon KC, Ochoa AC, Kopp WC, Ortaldo JR, Urba WJ, Longo DL, Young HA. Conlon KC, et al. Among authors: kopp wc. J Immunol. 1992 Nov 15;149(10):3278-89. J Immunol. 1992. PMID: 1358968

3

Correlation of human CD56+ cell cytotoxicity and IFN-gamma production.

Derby EG, Reddy V, Nelson EL, Kopp WC, Baseler MW, Dawson JR, Malyguine AM. Derby EG, et al. Among authors: kopp wc. Cytokine. 2001 Jan 21;13(2):85-90. doi: 10.1006/cyto.2000.0804. Cytokine. 2001. PMID: 11145847

4

Anti-CD3 monoclonal antibody treatment of patients with CD3-negative tumors: a phase IA/B study.

Urba WJ, Ewel C, Kopp W, Smith JW 2nd, Steis RG, Ashwell JD, Creekmore SP, Rossio J, Sznol M, Sharfman W, et al. Urba WJ, et al. Among authors: kopp w. Cancer Res. 1992 May 1;52(9):2394-401. Cancer Res. 1992. PMID: 1533172 Clinical Trial.

5

Influence of interleukin-2 regimens on circulating populations of lymphocytes after adoptive transfer of anti-CD3-stimulated T cells: results from a phase I trial in cancer patients.

Curti BD, Ochoa AC, Urba WJ, Alvord WG, Kopp WC, Powers G, Hawk C, Creekmore SP, Gause BL, Janik JE, Holmlund JT, Kremers P, Fenton RG, Miller L, Sznol M, Smith JW 2nd, Sharfman WH, Longo DL. Curti BD, et al. Among authors: kopp wc. J Immunother Emphasis Tumor Immunol. 1996 Jul;19(4):296-308. doi: 10.1097/00002371-199607000-00005. J Immunother Emphasis Tumor Immunol. 1996. PMID: 8877723 Clinical Trial.

6

CD8 gamma delta cells: presence in the adult rat thymus and generation in vitro from CD4-/CD8- thymocytes in the presence of interleukin 2.

Gotlieb WH, Takacs L, Finch LR, Kopp W, Weissman AM, Durum SK. Gotlieb WH, et al. Among authors: kopp w. Cytokine. 1991 Nov;3(6):598-608. doi: 10.1016/1043-4666(91)90487-x. Cytokine. 1991. PMID: 1838702

7

Immunomodulatory properties and toxicity of interleukin 2 in patients with cancer.

Urba WJ, Steis RG, Longo DL, Kopp WC, Maluish AE, Marcon L, Nelson DL, Stevenson HC, Clark JW. Urba WJ, et al. Among authors: kopp wc. Cancer Res. 1990 Jan 1;50(1):185-92. Cancer Res. 1990. PMID: 2293554

8

Polyinosinic-polycytidylic acid complexed with poly-L-lysine and carboxymethylcellulose in combination with interleukin 2 in patients with cancer: clinical and immunological effects.

Ewel CH, Urba WJ, Kopp WC, Smith JW 2nd, Steis RG, Rossio JL, Longo DL, Jones MJ, Alvord WG, Pinsky CM, et al. Ewel CH, et al. Among authors: kopp wc. Cancer Res. 1992 Jun 1;52(11):3005-10. Cancer Res. 1992. PMID: 1591717 Clinical Trial.

9

Three-color flow cytometric assay for the study of the mechanisms of cell-mediated cytotoxicity.

Derby E, Reddy V, Kopp W, Nelson E, Baseler M, Sayers T, Malyguine A. Derby E, et al. Among authors: kopp w. Immunol Lett. 2001 Aug 1;78(1):35-9. doi: 10.1016/s0165-2478(01)00226-7. Immunol Lett. 2001. PMID: 11470149

10

Immunomodulatory effects of interferon-gamma in patients with metastatic malignant melanoma.

Kopp WC, Smith JW 2nd, Ewel CH, Alvord WG, Main C, Guyre PM, Steis RG, Longo DL, Urba WJ. Kopp WC, et al. J Immunother Emphasis Tumor Immunol. 1993 Apr;13(3):181-90. doi: 10.1097/00002371-199304000-00005. J Immunother Emphasis Tumor Immunol. 1993. PMID: 8471592 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

310 results

Search Page

Filters